Latest Breaking News On - Irina kofflerinvestor - Page 1 : comparemela.com

Sol-Gel Technologies Ltd (SLGL) and Searchlight Pharma Enter Agreements to Commercialize TWYNEO and EPSOLAY in Canada

Sol-Gel Technologies Ltd (SLGL) and Searchlight Pharma Enter Agreements to Commercialize TWYNEO and EPSOLAY in Canada
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark nawackiIrina kofflerinvestorMark nawackipresidentGel technologies ltdExchange commissionCompany annual report on formSearchlight pharma incJesse ledgerchief strategy corporate developmentDrug administrationGel technologiesSearchlight pharmaAlon seri levyChief executive officerNorth americaPharma inc

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark nawackipresidentIrina kofflerinvestorMark nawackiGel technologies ltdDrug administrationSearchlight pharma incCompany annual report on formJesse ledgerchief strategy corporate developmentExchange commissionGel technologiesSearchlight pharmaAlon seri levyChief executive officerNorth americaPharma inc

Sol-Gel Technologies Ltd (SLGL) Acquires Patidegib

Sol-Gel Technologies Ltd (SLGL) Acquires Patidegib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesIrina kofflerinvestorMori arkinJulie breneiserEuropean medical associationGorlin syndrome allianceGel technologies ltdDrug administrationExchange commissionCompany annual report on formPellepharm incGel technologiesOrphan drug designationBreakthrough therapy designationChief executive officerExecutive director

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesIrina kofflerinvestorMori arkinJulie breneiserEuropean medical associationGorlin syndrome allianceGel technologies ltdDrug administrationExchange commissionCompany annual report on formPellepharm incWall streetOrphan drugSol gel technologiesOrphan drug designationBreakthrough therapy designation

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMichael glezinIrina kofflerinvestorCompany annual report on formExchange commissionGel technologies ltdBusiness developmentWall streetGel technologiesChief executive officerRecent corporateVice presidentPrivate securities litigation reform actAnnual reportLifesci advisorsSol gel technologies